Lead Product(s) : AK3280
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ArkBio Shows Strong Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis
Details : AK3280 is a potential next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : AK3280
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2025
Lead Product(s) : AK3280
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Connect Biopharma Starts Phase 2 COPD Study of Rademikibart for Exacerbations
Details : CBP-201 (rademikibart) binds to a distinct and unique region in IL-4R alpha for the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : CBP-201
Product Type : Antibody
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Connect Biopharma Starts Phase 2 Asthma Trial of Rademikibart
Details : CBP-201 (rademikibart) binds to a distinct and unique region in IL-4R alpha for the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : CBP-201
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Details : CBP-201 (rademikibart) binds to a distinct and unique region in IL-4R alpha for the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : CBP-201
Product Type : Antibody
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JYB1904
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Rapt Therapeutics
Deal Size : $707.5 million
Deal Type : Licensing Agreement
RAPT, Jemincare License Novel Anti-IgE Antibody With Long-Acting Therapeutic Effects
Details : The agreement aims for JYB1904/RPT904, a novel, half-life extended anti-IgE mAb for the treatment food allergies, chronic spontaneous urticaria and other allergic inflammatory diseases.
Product Name : RPT904
Product Type : Other Large Molecule
Upfront Cash : $35.0 million
December 23, 2024
Lead Product(s) : JYB1904
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Rapt Therapeutics
Deal Size : $707.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-201 (rademikibart) is an IL-4 alpha receptor Inhibitor Antibody drug candidate, which is being evaluated for the treatment of Moderate-to-Severe Asthma.
Product Name : CBP-201
Product Type : Antibody
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HSK31858
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to develop, manufacture, and commercialise outside China and adjacent territories, HSK31858, an oral, potent, and highly selective small molecule DPP1 inhibitor with the potential to be an anti-inflammatory agent in bronchiectasis.
Product Name : HSK31858
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 20, 2023
Lead Product(s) : HSK31858
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-201 (rademikibart) is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). It is in development for the treatment of atopic dermatitis (AD) and asthma.
Product Name : CBP-201
Product Type : Antibody
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Rademikibart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : QR052107B
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the MAD study have shown that QR052107B tablet at doses of 100 and 400 mg QD for 14 days was safe and well tolerated. Only one subject in the placebo treatment group withdrew due to an AE.
Product Name : QR052107B
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : QR052107B
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement
Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...
Product Name : AeroFact
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
December 22, 2021
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement